CN104918951B - 多粘菌素、组合物、制备方法和使用方法 - Google Patents

多粘菌素、组合物、制备方法和使用方法 Download PDF

Info

Publication number
CN104918951B
CN104918951B CN201480004714.8A CN201480004714A CN104918951B CN 104918951 B CN104918951 B CN 104918951B CN 201480004714 A CN201480004714 A CN 201480004714A CN 104918951 B CN104918951 B CN 104918951B
Authority
CN
China
Prior art keywords
uhplc
polymyxin
salt
methyloctanoyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480004714.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104918951A (zh
Inventor
索尔维·贡内斯
维达·比约恩斯塔
托本·科克
克莱斯·梅兰德
马丁·蒙森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xellia Pharmaceuticals ApS
Original Assignee
Xellia Pharmaceuticals ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals ApS filed Critical Xellia Pharmaceuticals ApS
Publication of CN104918951A publication Critical patent/CN104918951A/zh
Application granted granted Critical
Publication of CN104918951B publication Critical patent/CN104918951B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
CN201480004714.8A 2013-01-11 2014-01-09 多粘菌素、组合物、制备方法和使用方法 Active CN104918951B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361751341P 2013-01-11 2013-01-11
US61/751,341 2013-01-11
US201361904793P 2013-11-15 2013-11-15
US61/904,793 2013-11-15
PCT/EP2014/050320 WO2014108469A1 (en) 2013-01-11 2014-01-09 Polymyxins, compositions, methods of making and methods of use

Publications (2)

Publication Number Publication Date
CN104918951A CN104918951A (zh) 2015-09-16
CN104918951B true CN104918951B (zh) 2018-03-30

Family

ID=50101865

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480004714.8A Active CN104918951B (zh) 2013-01-11 2014-01-09 多粘菌素、组合物、制备方法和使用方法

Country Status (20)

Country Link
US (1) US10640536B2 (enExample)
EP (1) EP2943503B1 (enExample)
JP (1) JP6316846B2 (enExample)
KR (1) KR20150107793A (enExample)
CN (1) CN104918951B (enExample)
AU (1) AU2014204873B2 (enExample)
BR (1) BR112015016548A2 (enExample)
CA (1) CA2895910C (enExample)
EA (1) EA027067B1 (enExample)
ES (1) ES2641017T3 (enExample)
HU (1) HUE034562T2 (enExample)
IL (1) IL239840A (enExample)
MX (1) MX360905B (enExample)
PT (1) PT2943503T (enExample)
RU (1) RU2015132569A (enExample)
SI (1) SI2943503T1 (enExample)
TW (1) TWI613219B (enExample)
UA (1) UA117673C2 (enExample)
WO (1) WO2014108469A1 (enExample)
ZA (1) ZA201504565B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027067B1 (ru) 2013-01-11 2017-06-30 Кселлия Фармасьютикалз Апс Полимиксины, композиции, способы получения и способы применения
TW201522364A (zh) * 2013-06-07 2015-06-16 Xellia Pharmaceuticals Aps 黏菌素甲磺酸鈉（ｃｍｓ）之定性方法
JP2017523953A (ja) 2014-07-09 2017-08-24 クセリア ファーマシューティカルズ エーピーエスＸｅｌｌｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＡｐＳ 低置換度ポリミキシン及びその組成物
RS60874B1 (sr) 2014-10-03 2020-11-30 Xellia Pharmaceuticals Aps Kompozicije
SG11201702666SA (en) 2014-10-03 2017-04-27 Xellia Pharmaceuticals Aps Inhalation device
WO2016100578A2 (en) 2014-12-16 2016-06-23 Micurx Pharmaceuticals, Inc. Antimicrobial polymyxins for treatment of bacterial infections
FI126143B (en) * 2015-01-15 2016-07-15 Northern Antibiotics Oy Polymyxine derivative and its uses
AU2016331658B2 (en) * 2015-09-29 2021-04-01 Monash University Antimicrobial polymyxin derivative compounds
CN109996806B (zh) * 2016-12-09 2021-11-02 正大天晴药业集团股份有限公司 高效价的多黏菌素e2甲磺酸钠
CN115298198A (zh) 2020-01-21 2022-11-04 上海盟科药业股份有限公司 用于肾相关癌症靶向治疗的新型化合物和组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062895A (en) 1962-12-13 1967-03-22 Wellcome Found Sulphomethyl derivatives of polymxin
FR1586834A (enExample) 1968-02-12 1970-03-06
DE1906699A1 (de) 1968-02-12 1970-02-05 Pfizer Neue Polymyxinderivate und Verfahren zu deren Herstellung
EP0362370A1 (en) * 1988-04-07 1990-04-11 Edward Shanbrom Non-thrombogenic intravascular time release catheter
ATE202481T1 (de) 1996-11-15 2001-07-15 Pathogenesis Corp Reines, biologisch aktives colistin, seine bestandteile und eine colistin-zubereitung zur behandlung von entzündungen der atemwege
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
ES2261735T3 (es) 2001-05-18 2006-11-16 Chiron Corporation Sistema para la administracion de una formulacion de tobramicina.
US20040022740A1 (en) 2001-07-10 2004-02-05 Baker William R. Macrolide formulations for inhalation and methods of treatment of endobronchial infections
EP1940859A1 (en) * 2005-10-28 2008-07-09 Arch Pharmalabs Limited An improved process for preparation of gemcitabine hydrochloride
WO2008025560A1 (en) 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
WO2012168820A1 (en) 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
EA027067B1 (ru) 2013-01-11 2017-06-30 Кселлия Фармасьютикалз Апс Полимиксины, композиции, способы получения и способы применения
TW201522364A (zh) 2013-06-07 2015-06-16 Xellia Pharmaceuticals Aps 黏菌素甲磺酸鈉（ｃｍｓ）之定性方法
JP2017523953A (ja) 2014-07-09 2017-08-24 クセリア ファーマシューティカルズ エーピーエスＸｅｌｌｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＡｐＳ 低置換度ポリミキシン及びその組成物
RS60874B1 (sr) 2014-10-03 2020-11-30 Xellia Pharmaceuticals Aps Kompozicije

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Colistin methanesulfonate is an inactive prodrug of colistin against pseudomonas aeruginosa;Bergen等;《Antimicrob agents chemother.》;20060630;第50卷(第6期);第1953页右侧,第1956页右侧最后1段,第1957页左侧,图1a和1b *
Novel polymyxin derivatives carryting only three positive charges are effective antibacterial agents;Vaara等;《Antimicrobial agents and chemotherapy》;20080930;第52卷(第9期);3229-3236 *
Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography;LI等;《Antimicrob.agents.chemother.》;20030430;第47卷(第4期);1364-1370 *

Also Published As

Publication number Publication date
KR20150107793A (ko) 2015-09-23
EP2943503A1 (en) 2015-11-18
RU2015132569A (ru) 2017-02-14
CN104918951A (zh) 2015-09-16
ES2641017T3 (es) 2017-11-07
JP2016505007A (ja) 2016-02-18
SI2943503T1 (sl) 2017-11-30
CA2895910A1 (en) 2014-07-17
US10640536B2 (en) 2020-05-05
MX360905B (es) 2018-11-21
TW201429995A (zh) 2014-08-01
US20160002296A1 (en) 2016-01-07
CA2895910C (en) 2021-12-21
UA117673C2 (uk) 2018-09-10
AU2014204873A1 (en) 2015-07-09
AU2014204873B2 (en) 2017-07-06
MX2015008878A (es) 2015-10-30
IL239840A (en) 2017-09-28
IL239840A0 (en) 2015-08-31
EA201591280A1 (ru) 2015-12-30
HUE034562T2 (en) 2018-03-28
JP6316846B2 (ja) 2018-04-25
EA027067B1 (ru) 2017-06-30
EP2943503B1 (en) 2017-08-23
TWI613219B (zh) 2018-02-01
WO2014108469A1 (en) 2014-07-17
ZA201504565B (en) 2016-11-30
PT2943503T (pt) 2017-09-28
BR112015016548A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
CN104918951B (zh) 多粘菌素、组合物、制备方法和使用方法
JP6091596B2 (ja) 高純度シクロペプチド化合物およびその製造方法と使用
WO2012168820A1 (en) Polymyxin derivatives useful as antibacterial agents
AU2016331658A1 (en) Antimicrobial polymyxin derivative compounds
CA2949328C (en) Low substituted polymyxins and compositions thereof
US8410044B2 (en) Bacitracin antibiotics
JP7505978B2 (ja) 線状リポペプチドパエニペプチン及びそれを使用する方法
AU2022235282A1 (en) Stapled antimicrobial peptides (stamps) and uses thereof
CN116425838A (zh) 多肽化合物及其医药用途
HK40059901B (zh) 脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant